What is the recommended dosing regimen for amiodarone (antiarrhythmic medication)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amiodarone Dosing Regimen

For amiodarone therapy, the recommended dosing regimen includes a loading dose of 400-600 mg daily in divided doses for 2-4 weeks, followed by a maintenance dose of 100-200 mg daily to minimize long-term adverse effects. 1

Intravenous Administration for Acute Situations

Life-Threatening Arrhythmias

  • Initial dose: 150 mg IV bolus over 10 minutes
    • May be repeated in 10-30 minutes if necessary
  • Follow with: 1 mg/minute for 6 hours
  • Then: 0.5 mg/minute for 18 hours
  • Administration considerations:
    • Use volumetric infusion pump
    • Preferably administer through central venous catheter
    • Use in-line filter
    • Avoid concentrations >3 mg/mL due to phlebitis risk 1, 2

Oral Administration by Indication

Ventricular Arrhythmias

  • Loading dose: 800-1,600 mg/day in divided doses until total of 10g is given
  • Maintenance dose: 200-400 mg/day 1, 2

Atrial Fibrillation

  • Loading dose: 600-800 mg/day in divided doses until total of 10g is given
  • Maintenance dose: 200 mg/day 1, 2

Transition from IV to Oral Therapy

When switching from IV to oral administration, dosing depends on duration of IV therapy:

  • IV therapy <1 week: 800-1,600 mg oral amiodarone daily
  • IV therapy 1-3 weeks: 600-800 mg oral amiodarone daily
  • IV therapy >3 weeks: 400 mg oral amiodarone daily 1

Dosing Considerations and Precautions

Dose Adjustments

  • Use lowest effective dose (preferably ≤300 mg/day) when possible 2
  • Maximum daily dose: Up to 1,200 mg daily may be considered in inpatient monitoring settings (loading dose) 1
  • Reduce dose by 30%-50% when administering with digoxin 1
  • Reduce warfarin dose by 50% when co-administered with amiodarone 1

Monitoring Requirements

  • Baseline and follow-up (every 3-6 months) thyroid function tests (TSH, free T4, T3)
  • Baseline pulmonary function tests including DLCO
  • Chest imaging (X-ray or high-resolution CT) at baseline and periodically
  • Regular clinical assessment for adverse effects 2

Common Adverse Effects to Monitor

  • Cardiovascular: Bradycardia, QT prolongation, hypotension, AV block
  • Pulmonary: Cough, dyspnea, interstitial infiltrates (serious complication)
  • Gastrointestinal: GI upset, constipation
  • Neurological: Tremor, ataxia
  • Thyroid: Hypo/hyperthyroidism
  • Ophthalmologic: Corneal microdeposits, visual disturbances 1, 2

Important Contraindications

  • Severe sinus node dysfunction
  • AV block greater than first degree (without pacemaker)
  • Cardiogenic shock
  • Known hypersensitivity to amiodarone or iodine
  • Pregnancy and lactation 2

Amiodarone shows considerable interindividual variation in response, requiring close monitoring and dose adjustment. The drug has a very long half-life (approximately 30 days), which explains the prolonged loading phase and persistent effects after discontinuation 3, 4.

While high-dose amiodarone (600-800 mg/day) has been used historically 5, 6, current guidelines favor lower maintenance doses (100-200 mg daily) to minimize long-term adverse effects while maintaining efficacy 1, 2.

The key to successful amiodarone therapy is balancing efficacy with toxicity through appropriate dosing and vigilant monitoring of potential adverse effects.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Amiodarone Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ten years of experience with amiodarone.

American heart journal, 1983

Research

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.

Journal of the American College of Cardiology, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.